Lactoferrin assumption in vaccinated subjects infected by SARS-CoV-2 may influence time length of negativization

Abstract: Abstracts P-196 PREP ACCESS HIGHLIGHTS WORRISOME GAP IN VACCINATION COVERAGE AGAINST HPV AND OTHER VACCINE PREVENTABLE STIS R Fattore, A Giacomelli, MV Cossu, F Barone, C Fusetti, F Caruso, G Scaglione, F Fama, M Gerbi, P Raimondo, A Gori, D Moschese. Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy gap and access barriers in pivotal preventive interventions that deserve to be urgently filled. In particular, campaigns to inform about the importance of HPV vaccine before the start of sexual activity irrespectively of gender are urgently needed. 10.1136/sextrans-ICAR-2024.255 Introduction PrEP use is rapidly increasing in Italy since its full reimbursement by the National Health System. PrEP allows STIs-exposed individuals to be managed in appropriate settings and being offered a number of preventing interventions. Among these, preventive vaccines against STIs are pivotal interventions among PrEP users. Aim of our study was to assess the prevalence of STIs vaccine coverage at the time of PrEP start as well as acceptability rate of newly vaccine offered. Materials and Methods All individuals who accessed our PrEP service (Luigi Sacco Hospital outpatient STIs clinic, Milan, Italy) between January 2022 and February 2024 were included. Vaccination status was ascertained at the time of PrEP start by means of clinical interview and the assessment of the electronic vaccine certification when available. All unvaccinated individuals were proposed to receive HPV vaccination and all other available vaccines against STIs. Results During the study period, 348 individuals started PrEP at our center, primarily MSM (98%), along with 5 transgender women (1,4%) and 3 cisgender women (0.9%). 251 (72.3%) individuals resulted HPV and/or other STIs-vaccine unexposed at the time of PrEP start. All but 1 individual started the STIs vaccination schedule: 210 underwent HPV vaccination, while 40 were already HPV-immunized and received other vaccines. Remarkably, over 99% of these patients immediately accepted the vaccination cycle when proposed. Conclusions The vaccination coverage for vaccine preventable STIs is worrisome low in people who presented at our STIs outpatient clinic to start PrEP. The immediate vaccine acceptance by almost all individuals highlights a serious information A262 P-197 LACTOFERRIN ASSUMPTION IN VACCINATED SUBJECTS INFECTED BY SARS-COV-2 MAY INFLUENCE TIME LENGTH OF NEGATIVIZATION 1 G Costanza, 2T Cosio, 1M Ciotti, 3C Lanna, 4L Rosa, 3C Galluzzi, 2R Gaziano, 1S Grelli, P Valenti, 3L Bianchi, 3E Campione. 1Unit of Virology, Tor Vergata University Hospital, Rome, Italy; 2Department of Experimental Medicine, Tor Vergata University Hospital, Rome, Italy; 3Dermatology Unit, Department of Systems Medicine, Tor Vergata University Hospital, Rome, Italy; 4Department of Public Health and Infectious Diseases, University of Rome La Sapienza, Rome, Italy 4 10.1136/sextrans-ICAR-2024.256 Background The pandemic due to SARS-CoV-2 infection comported enormous changes from every point of view, from social habits to certainties in the scientific world in the last 3 years. Measures, such as lock-down of communities, social distancing, and quarantine-type for those suspected to be infected slowed down the COronaVIrus Disease 19 spread. Lactoferrin (Lf), a glycoprotein of the transferrin family, was used as ‘alternative remedy against COVID-19’. Methods We conducted a randomized, double-blind, two-arm study..